<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35506234</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Targeting carbonic anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>1278</StartPage>
          <EndPage>1298</EndPage>
          <MedlinePgn>1278-1298</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2052868</ELocationID>
        <Abstract>
          <AbstractText>Carbonic anhydrases IX and CAXII (CAIX/CAXII) are transmembrane zinc metalloproteins that catalyze a very basic but crucial physiological reaction: the conversion of carbon dioxide into bicarbonate with a release of the proton. CA, especially CAIX and CAXII isoforms gained the attention of many researchers interested in anticancer drug design due to pivotal functions of enzymes in the cancer cell metastasis and response to hypoxia, and their expression restricted to malignant cells. This offers an opportunity to develop new targeted therapies with fewer side effects. Continuous efforts led to the discovery of a series of diverse compounds with the most abundant sulphonamide derivatives. Here we review current knowledge considering small molecule and antibody-based targeting of CAIX/CAXII in cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kciuk</LastName>
            <ForeName>Mateusz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biotechnology and Genetics, Laboratory of Cytogenetics, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Doctoral School of Exact and Natural Sciences, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gielecińska</LastName>
            <ForeName>Adrianna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biotechnology and Genetics, Laboratory of Cytogenetics, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mujwar</LastName>
            <ForeName>Somdutt</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Pharmaceutical Research, GLA University, Mathura, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mojzych</LastName>
            <ForeName>Mariusz</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Siedlce University of Natural Sciences and Humanities, Siedlce, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marciniak</LastName>
            <ForeName>Beata</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biotechnology and Genetics, Laboratory of Cytogenetics, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drozda</LastName>
            <ForeName>Rafał</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastrointestinal Endoscopy, Wl. Bieganski Hospital, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kontek</LastName>
            <ForeName>Renata</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biotechnology and Genetics, Laboratory of Cytogenetics, University of Lodz, Lodz, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D000071231">Carbonic Anhydrase IX</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071231" MajorTopicYN="N">Carbonic Anhydrase IX</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002256" MajorTopicYN="Y">Carbonic Anhydrases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Cancer</Keyword>
        <Keyword MajorTopicYN="N">carbonic anhydrase</Keyword>
        <Keyword MajorTopicYN="N">inhibitor</Keyword>
        <Keyword MajorTopicYN="N">sulphonamides</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>3</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35506234</ArticleId>
        <ArticleId IdType="pmc">PMC9090362</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2052868</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Supuran CT.
Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov
2008;7:168–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18167490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Structure and function of carbonic anhydrases. Biochem J
2016;473:2023–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27407171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinard MA, Mahon B, McKenna R.. 
Probing the surface of human carbonic anhydrase for clues towards the design of isoform specific inhibitors. Biomed Res Int
2015;2015:453543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4355338</ArticleId>
            <ArticleId IdType="pubmed">25811028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ.. 
Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness. Metabolites. 2018;8:13.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakagawa Y, Uemura H, Hirao Y, Yoshida K, Saga S, Yoshikawa K.. 
Radiation hybrid mapping of the human MN/CA9 locus to chromosome band 9p12-p13. Genomics. 1998;53:118–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9787087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opavský R, Pastoreková S, Zelník V, et al. . 
Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics
1996;33:480–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8661007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waheed A, Sly WS, Doisy EA.. 
Carbonic anhydrase XII functions in health and disease. Gene
2017;623:33–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5851007</ArticleId>
            <ArticleId IdType="pubmed">28433659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastorek J, Pastorekova S.. 
Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol. 2015;31:52–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25117006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mboge MY, McKenna R, Frost SC.. 
Advances in anti-cancer drug development targeting carbonic anhydrase IX and XII. Top Anticancer Res
2015;5:3–42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6162069</ArticleId>
            <ArticleId IdType="pubmed">30272043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahon BP, Pinard MA, McKenna R.. 
Targeting carbonic anhydrase IX activity and expression. Molecules
2015;20:2323–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6272707</ArticleId>
            <ArticleId IdType="pubmed">25647573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh S, Lomelino CL, Mboge MY, Frost SC, McKenna R.. 
Cancer drug development of carbonic anhydrase inhibitors beyond the active site. Molecules
2018;23:1045.</Citation>
        </Reference>
        <Reference>
          <Citation>Imtaiyaz Hassan M, Shajee B, Waheed A, Ahmad F, Sly WS.. 
Structure, function and applications of carbonic anhydrase isozymes. Bioorg Med Chem
2013;21:1570–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22607884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Simone G, Supuran CT.. 
Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim Biophys Acta
2010;1804:404–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19679200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hulikova A, Zatovicova M, Svastova E, et al. . 
Intact intracellular tail is critical for proper functioning of the tumor-associated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett
2009;583:3563–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19861127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald PC, Winum JY, Supuran CT, Dedhar S.. 
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget
2012;3:84–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3292895</ArticleId>
            <ArticleId IdType="pubmed">22289741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welch DR, Hurst DR.. 
Defining the hallmarks of metastasis. Cancer Res
2019;79:3011–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6571042</ArticleId>
            <ArticleId IdType="pubmed">31053634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel SA, Vanharanta S.. 
Epigenetic determinants of metastasis. Mol Oncol
2017;11:79–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5423227</ArticleId>
            <ArticleId IdType="pubmed">27756687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García SA, Weitz J, Schölch S.. 
Circulating tumor cells. Methods Mol Biol
2018;1692:213–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28986899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balzer EM, Konstantopoulos K.. 
Intercellular adhesion: mechanisms for growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol Med
2012;4:171–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4476647</ArticleId>
            <ArticleId IdType="pubmed">21913338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratcliffe PJ.
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. J Physiol
2013;591:2027–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3634517</ArticleId>
            <ArticleId IdType="pubmed">23401619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muz B, de la Puente P, Azab F, Azab AK.. 
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia
2015;3:83–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5045092</ArticleId>
            <ArticleId IdType="pubmed">27774485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paredes F, Williams HC, San Martin A.. 
Metabolic adaptation in hypoxia and cancer. Cancer Lett
2021;502:133–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8158653</ArticleId>
            <ArticleId IdType="pubmed">33444690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Damaghi M, Wojtkowiak JW, Gillies RJ.. 
pH sensing and regulation in cancer. Front Physiol
2013;4:370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3865727</ArticleId>
            <ArticleId IdType="pubmed">24381558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McIntyre A, Harris AL.. 
The role of pH regulation in cancer progression. Recent Results Cancer Res
2016;207:93–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27557536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koltai T.
Cancer: fundamentals behind pH targeting and the double-edged approach. Onco Targets Ther
2016;9:6343–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5074768</ArticleId>
            <ArticleId IdType="pubmed">27799782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parks SK, Pouysségur J.. 
Targeting pH regulating proteins for cancer therapy-progress and limitations. Semin Cancer Biol
2017;43:66–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28137473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asgharzadeh MR, Barar J, Pourseif MM, et al. . 
Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. Bioimpacts
2017;7:115–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5524986</ArticleId>
            <ArticleId IdType="pubmed">28752076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cluntun AA, Lukey MJ, Cerione RA, Locasale JW.. 
Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer
2017;3:169–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5383348</ArticleId>
            <ArticleId IdType="pubmed">28393116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Le A.. 
Glutamine metabolism in cancer. Adv Exp Med Biol
2018;1063:13–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29946773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y.. 
Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther
2020;5:28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7067809</ArticleId>
            <ArticleId IdType="pubmed">32296047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miranda-Gonçalves V, Granja S, Martinho O, et al. . 
Hypoxia-mediated upregulation of MCT1 expression supports the glycolytic phenotype of glioblastomas. Oncotarget
2016;7:46335–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5216802</ArticleId>
            <ArticleId IdType="pubmed">27331625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine AJ, Puzio-Kuter AM.. 
The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science
2010;330:1340–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21127244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen DX, Massagué J.. 
Genetic determinants of cancer metastasis. Nat Rev Genet
2007;8:341–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17440531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang AC, Massagué J.. 
Molecular basis of metastasis. N Engl J Med
2008;359:2814–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4189180</ArticleId>
            <ArticleId IdType="pubmed">19109576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaelin WG, Ratcliffe PJ.. 
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell
2008;30:393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18498744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lendahl U, Lee KL, Yang H, Poellinger L.. 
Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet
2009;10:821–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19884889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L.. 
Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem
2006;281:25903–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132567</ArticleId>
            <ArticleId IdType="pubmed">16847054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith K, Gunaratnam L, Morley M, Franovic A, Mekhail K, Lee S.. 
Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL–/– renal cancer. Cancer Res
2005;65:5221–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15958567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SH, Koo KH, Park JW, et al. . 
HIF-1 is induced via EGFR activation and mediates resistance to anoikis-like cell death under lipid rafts/caveolae-disrupting stress. Carcinogenesis
2009;30:1997–2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19789263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Guerrab A, Zegrour R, Nemlin CC, et al. . 
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLOS One
2011;6:e25080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3178587</ArticleId>
            <ArticleId IdType="pubmed">21966417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q li, Cui B ri, Li H yan, et al. . 
MAPK and PI3K pathways regulate hypoxia-induced atrial natriuretic peptide secretion by controlling HIF-1 alpha expression in beating rabbit atria. Biochem Biophys Res Commun
2013;438:507–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23916614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V, Caro J.. 
MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem
2003;278:14013–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4518846</ArticleId>
            <ArticleId IdType="pubmed">12588875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khandrika L, Lieberman R, Koul S, et al. . 
Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer. Oncogene
2009;28:1248–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2651999</ArticleId>
            <ArticleId IdType="pubmed">19151763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Z, Yao L, Yang J, Wang Z, Du G.. 
PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia. Mol Med Rep
2018;18:3547–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6131612</ArticleId>
            <ArticleId IdType="pubmed">30106145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK.. 
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ
2001;12:363–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11457733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ditte P, Dequiedt F, Svastova E, et al. . 
Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res
2011;71:7558–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22037869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corbet C, Feron O.. 
Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer
2017;17:577–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28912578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wykoff CC, Beasley NJ, Watson PH, et al. . Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res
2000;60:7075–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11156414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chia SK, Wykoff CC, Watson PH, et al. . 
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol
2001;19:3660–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11504747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hynninen P, Vaskivuo L, Saarnio J, et al. . 
Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology
2006;49:594–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17163844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panisova E, Kery M, Sedlakova O, et al. . 
Lactate stimulates CA IX expression in normoxic cancer cells. Oncotarget
2017;8:77819–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5652817</ArticleId>
            <ArticleId IdType="pubmed">29100428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiaschi T, Giannoni E, Taddei ML, et al. . 
Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle
2013;12:1791–801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3713137</ArticleId>
            <ArticleId IdType="pubmed">23656776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ.. 
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?
Biochim Biophys Acta
2009;1795:162–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670353</ArticleId>
            <ArticleId IdType="pubmed">19344680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stillebroer AB, Mulders PFA, Boerman OC, Oyen WJG, Oosterwijk E.. 
Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol
2010;58:75–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20359812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubois L, Peeters S, Lieuwes NG, et al. . 
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol
2011;99:424–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21676479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Jiang L, Chew SH, Hirayama T, Sekido Y, Toyokuni S.. 
Carbonic anhydrase 9 confers resistance to ferroptosis/apoptosis in malignant mesothelioma under hypoxia. Redox Biol
2019;26:101297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6831888</ArticleId>
            <ArticleId IdType="pubmed">31442913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Webb BA, Chimenti M, Jacobson MP, Barber DL.. 
Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer
2011;11:671–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21833026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Persi E, Duran-Frigola M, Damaghi M, et al. . 
Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun
2018;9:2997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6068141</ArticleId>
            <ArticleId IdType="pubmed">30065243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansone P, Piazzi G, Paterini P, et al. . 
Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells. J Cell Mol Med
2009;13:3876–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4516535</ArticleId>
            <ArticleId IdType="pubmed">19017360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson N, Potter C, Harris AL.. 
Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res
2004;64():6160–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15342400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swayampakula M, McDonald PC, Vallejo M, et al. . 
The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene
2017;36:6244–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5684442</ArticleId>
            <ArticleId IdType="pubmed">28692057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radvak P, Repic M, Svastova E, et al. . 
Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol Rep
2013;29:1147–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23291973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujiwara D, Kato K, Nohara S, Iwanuma Y, Kajiyama Y.. 
The usefulness of three-dimensional cell culture in induction of cancer stem cells from esophageal squamous cell carcinoma cell lines. Biochem Biophys Res Commun
2013;434:773–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23602898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Axelson H, Fredlund E, Ovenberger M, Landberg G, Påhlman S.. 
Hypoxia-induced dedifferentiation of tumor cells–a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol
2005;16:554–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16144692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lock FE, McDonald PC, Lou Y, et al. . 
Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene
2013;32:5210–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23208505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currie MJ, Beardsley BE, Harris GC, et al. . 
Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol
2013;44:402–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23036368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Svastová E, Zilka N, Zat’ovicová M, et al. . 
Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp Cell Res
2003;290:332–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14567991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin HJ, Rho SB, Jung DC, Han IO, Oh ES, Kim JY.. 
Carbonic anhydrase IX (CA9) modulates tumor-associated cell migration and invasion. J Cell Sci
2011;124:1077–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21363891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourguignon LYW, Singleton PA, Diedrich F, Stern R, Gilad E.. 
CD44 interaction with Na+-H + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem
2004;279:26991–7007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15090545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bourguignon LY, Zhu H, Shao L, Chen YW.. 
CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration. J Biol Chem
2001;276:7327–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11084024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Csaderova L, Debreova M, Radvak P, et al. . 
The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Front Physiol
2013;4:271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3787331</ArticleId>
            <ArticleId IdType="pubmed">24101905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riemann A, Rauschner M, Gießelmann M, Reime S, Haupt V, Thews O.. 
Extracellular acidosis modulates the expression of epithelial-mesenchymal transition (EMT) markers and adhesion of epithelial and tumor cells. Neoplasia. 2019;21:450–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6447725</ArticleId>
            <ArticleId IdType="pubmed">30953950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pastorekova S, Gillies RJ.. 
The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev
2019;38:65–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6647366</ArticleId>
            <ArticleId IdType="pubmed">31076951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jamali S, Klier M, Ames S, et al. . 
Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep
2015;5:13605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4559800</ArticleId>
            <ArticleId IdType="pubmed">26337752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deitmer JW, Theparambil SM, Ruminot I, Becker HM.. 
The role of membrane acid/base transporters and carbonic anhydrases for cellular pH and metabolic processes. Front Neurosci
2015;8:430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4283522</ArticleId>
            <ArticleId IdType="pubmed">25601823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald PC, Swayampakula M, Dedhar S.. 
Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX. Metabolites
2018;8:E20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5876009</ArticleId>
            <ArticleId IdType="pubmed">29517989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pore N, Jalla S, Liu Z, et al. . 
In vivo loss of function screening reveals carbonic anhydrase IX as a key modulator of tumor initiating potential in primary pancreatic tumors. Neoplasia
2015;17:473–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4719001</ArticleId>
            <ArticleId IdType="pubmed">26152355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zandberga E, Zayakin P, Ābols A, Pūpola D, Trapencieris P, Linē A.. 
Depletion of carbonic anhydrase IX abrogates hypoxia-induced overexpression of stanniocalcin-1 in triple negative breast cancer cells. Cancer Biol Ther
2017;18:596–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5653187</ArticleId>
            <ArticleId IdType="pubmed">28665755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doyen J, Parks SK, Marcié S, Pouysségur J, Chiche J.. 
Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis. Front Oncol
2013;2:199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3539669</ArticleId>
            <ArticleId IdType="pubmed">23316475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Xu G, Li Z, et al. . 
RNAi-mediated knockdown of CAIX enhances the radiosensitivity of nasopharyngeal carcinoma cell line, CNE-2. Onco Targets Ther
2017;10:4701–09.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5626387</ArticleId>
            <ArticleId IdType="pubmed">29026318</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gut MO, Parkkila S, Vernerová Z, et al. . 
Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology
2002;123:1889–1903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12454846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan P wen, Parkkila AK, Autio S, et al. . 
Brain phenotype of carbonic anhydrase IX-deficient mice. Transgenic Res
2012;21:163–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21547424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li T, Liu X, Riederer B, et al. . 
Genetic ablation of carbonic anhydrase IX disrupts gastric barrier function via claudin-18 downregulation and acid backflux. Acta Physiol
2018;222:e12923.</Citation>
        </Reference>
        <Reference>
          <Citation>Pastoreková S, Parkkila S, Parkkila AK, et al. . 
Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology
1997;112:398–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9024293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordfors K, Haapasalo J, Korja M, et al. . 
The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer
2010;10:148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2874782</ArticleId>
            <ArticleId IdType="pubmed">20398423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilie MI, Hofman V, Ortholan C, et al. . 
Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer
2011;128:1614–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20521252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tafreshi NK, Lloyd MC, Proemsey JB, et al. . 
Evaluation of CAIX and CAXII expression in breast cancer at varied O2 levels: CAIX is the superior surrogate imaging biomarker of tumor hypoxia. Mol Imaging Biol
2016;18:219–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4754166</ArticleId>
            <ArticleId IdType="pubmed">26276155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F, Brawanski A.. 
Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol
2012;14:1357–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3480266</ArticleId>
            <ArticleId IdType="pubmed">23074198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cetin B, Gonul II, Gumusay O, et al. . 
Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme. Neuropathology
2018;38:457–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29952031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McIntyre A, Patiar S, Wigfield S, et al. . 
Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res
2012;18:3100–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367109</ArticleId>
            <ArticleId IdType="pubmed">22498007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ.. 
Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm
2011;8:2032–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3230683</ArticleId>
            <ArticleId IdType="pubmed">21981633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vullo D, Franchi M, Gallori E, et al. . 
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett
2003;13:1005–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12643899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alterio V, Di Fiore A, D’Ambrosio K, Supuran CT, De Simone G.. 
Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?
Chem Rev
2012;112:4421–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22607219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKenna R, Supuran CT.. 
Carbonic anhydrase inhibitors drug design. Subcell Biochem
2014;75:291–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24146385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anduran E, Aspatwar A, Parvathaneni NK, et al. . 
Hypoxia-activated prodrug derivatives of carbonic anhydrase inhibitors in benzenesulfonamide series: synthesis and biological evaluation. Molecules
2020;25:E2347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7287649</ArticleId>
            <ArticleId IdType="pubmed">32443462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong BCK, Zhang H, Qin L, et al. . 
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Devel Ther
2014;8:993–1001.</Citation>
        </Reference>
        <Reference>
          <Citation>Ng HLH, Lu A, Lin G, Qin L, Yang Z.. 
The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo. Int J Mol Sci
2014;16:230–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4307245</ArticleId>
            <ArticleId IdType="pubmed">25547490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lou Y, McDonald PC, Oloumi A, et al. . 
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res
2011;71:3364–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21415165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gieling RG, Babur M, Mamnani L, et al. . 
Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem
2012;55:5591–600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22621623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahlskog JKJ, Dumelin CE, Trüssel S, Mårlind J, Neri D.. 
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009;19:4851–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19615903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cianchi F, Vinci MC, Supuran CT, et al. . 
Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther
2010;334:710–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20519553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pacchiano F, Carta F, McDonald PC, et al. . 
Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem
2011;54:1896–902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21361354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vannozzi G, Vullo D, Angeli A, et al. . 
One-pot procedure for the synthesis of asymmetric substituted ureido benzene sulfonamides as effective inhibitors of carbonic anhydrase enzymes. J Med Chem. 2022;65:824–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34958217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyuncu I, Tülüce Y, Slahaddin Qadir H, Durgun M, Supuran CT.. 
Evaluation of the anticancer potential of a sulphonamide carbonic anhydrase IX inhibitor on cervical cancer cells. J Enzyme Inhib Med Chem
2019;34:703–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6394301</ArticleId>
            <ArticleId IdType="pubmed">30810431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tülüce Y, Ahmed BA, Koyuncu İ, Durgun M.. 
The cytotoxic, apoptotic and oxidative effects of carbonic anhydrase IX inhibitor on colorectal cancer cells. J Bioenerg Biomembr
2018;50:107–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29520697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winum JY, Vullo D, Casini A, Montero JL, Scozzafava A, Supuran CT.. 
Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem
2003;46:2197–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pettersen EO, Ebbesen P, Gieling RG, et al. . 
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem
2015;30:689–721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25347767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hektoen HH, Ree AH, Redalen KR, Flatmark K.. 
Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells. J Enzyme Inhib Med Chem
2016;31:779–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26244271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward C, Meehan J, Mullen P, et al. . 
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget
2015;6:24856–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4694798</ArticleId>
            <ArticleId IdType="pubmed">26259239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raez L, Samuels M, Lilenbaum R.. 
Combined modality therapy for limited-disease small cell lung cancer. Curr Treat Options Oncol
2005;6:69–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15610716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryant JL, Gieling RG, Meredith SL, et al. . 
Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer
2018;142:191–201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28905987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gieling RG, Parker CA, De Costa LA, et al. . 
Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro. J Enzyme Inhib Med Chem
2013;28:360–369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23163664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buller F, Steiner M, Frey K, et al. . 
Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds. ACS Chem Biol. 2011;6:336–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21186831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tykvart J, Navrátil V, Kugler M, et al. . 
Identification of novel carbonic anhydrase IX inhibitors using high-throughput screening of pooled compound libraries by DNA-linked inhibitor antibody assay (DIANA). SLAS Discov
2020;25:1026–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32452709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chahal V, Nirwan S, Pathak M, Kakkar R.. 
Identification of potent human carbonic anhydrase IX inhibitors: a combination of pharmacophore modeling, 3D-QSAR, virtual screening and molecular dynamics simulations. J Biomol Struct Dyn
2020;15:1–16.</Citation>
        </Reference>
        <Reference>
          <Citation>Lomelino CL, Murray AB, Supuran CT, McKenna R.. 
Sweet binders: carbonic anhydrase IX in complex with sucralose. ACS Med Chem Lett
2018;9:657–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6047028</ArticleId>
            <ArticleId IdType="pubmed">30034596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuffaro D, Nuti E, Rossello A.. 
An overview of carbohydrate-based carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem
2020;35:1906–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7717713</ArticleId>
            <ArticleId IdType="pubmed">33078634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winum JY, Colinas PA, Supuran CT.. 
Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer. Bioorg Med Chem
2013;21:1419–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23199483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreucci E, Ruzzolini J, Peppicelli S, et al. . 
The carbonic anhydrase IX inhibitor SLC-0111 sensitises cancer cells to conventional chemotherapy. J Enzyme Inhib Med Chem. 2019;34:117–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6211231</ArticleId>
            <ArticleId IdType="pubmed">30362384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peppicelli S, Andreucci E, Ruzzolini J, et al. . 
The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells. J Enzyme Inhib Med Chem
2020;35:1185–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7269050</ArticleId>
            <ArticleId IdType="pubmed">32396749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riemann A, Güttler A, Haupt V, et al. . 
Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity. Oncol Res
2018;26:191–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7844713</ArticleId>
            <ArticleId IdType="pubmed">28631600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mussi S, Rezzola S, Chiodelli P, Nocentini A, Supuran CT, Ronca R.. 
Antiproliferative effects of sulphonamide carbonic anhydrase inhibitors C18, SLC-0111 and acetazolamide on bladder, glioblastoma and pancreatic cancer cell lines. J Enzyme Inhib Med Chem
2022;37:280–286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8667884</ArticleId>
            <ArticleId IdType="pubmed">34894950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli A, Carta F, Nocentini A, et al. . 
Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10:412.</Citation>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27:963–70.</Citation>
        </Reference>
        <Reference>
          <Citation>McDonald PC, Chia S, Bedard PL, et al. . 
A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol
2020;43:484–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7323835</ArticleId>
            <ArticleId IdType="pubmed">32251122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs
2021;30:1197–208.</Citation>
        </Reference>
        <Reference>
          <Citation>Elimam DM, Eldehna WM, Salem R, et al. . 
Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors. Eur J Med Chem
2022;228:114008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34871842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elbadawi MM, Eldehna WM, Nocentini A, et al. . 
Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: synthesis and evaluation of the carbonic anhydrase inhibitory activities. Eur J Med Chem
2021;218:113360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33773285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaldam M, Eldehna WM, Nocentini A, et al. . 
Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Eur J Med Chem
2021;216:113283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33667848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams KJ, Gieling RG.. 
Preclinical evaluation of ureidosulfamate carbonic anhydrase IX/XII inhibitors in the treatment of cancers. Int J Mol Sci
2019;20:E6080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6928609</ArticleId>
            <ArticleId IdType="pubmed">31810330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mboge MY, Combs J, Singh S, et al. . 
Inhibition of carbonic anhydrase using SLC-149: support for a noncatalytic function of CAIX in breast cancer. J Med Chem
2021;64:1713–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33523653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarnella A, D’Avino G, Hill BS, et al. . 
A novel inhibitor of carbonic anhydrases prevents hypoxia-induced TNBC cell plasticity. Int J Mol Sci
2020;21:8405.</Citation>
        </Reference>
        <Reference>
          <Citation>Krasavin M, Kalinin S, Sharonova T, Supuran CT.. 
Inhibitory activity against carbonic anhydrase IX and XII as a candidate selection criterion in the development of new anticancer agents. J Enzyme Inhib Med Chem
2020;35:1555–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470080</ArticleId>
            <ArticleId IdType="pubmed">32746643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dvořanová J, Kugler M, Holub J, et al. . 
Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX. Eur J Med Chem
2020;200:112460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32505851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kugler M, Holub J, Brynda J, et al. . 
The structural basis for the selectivity of sulfonamido dicarbaboranes toward cancer-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem
2020;35:1800–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534198</ArticleId>
            <ArticleId IdType="pubmed">32962427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma V, Kumar R, Angeli A, Supuran CT, Sharma PK.. 
Tail approach synthesis of novel benzenesulfonamides incorporating 1,3,4-oxadiazole hybrids as potent inhibitor of carbonic anhydrase I, II, IX, and XII isoenzymes. Eur J Med Chem
2020;193:112219.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32203788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uslu AG, Gür Maz T, Nocentini A, Banoglu E, Supuran CT, Çalışkan B.. 
Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors. Bioorg Chem
2020;95:103544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31915112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pustenko A, Nocentini A, Balašova A, Krasavin M, Žalubovskis R, Supuran CT.. 
7-Acylamino-3H-1,2-benzoxathiepine 2,2-dioxides as new isoform-selective carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem
2020;35:650–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7048192</ArticleId>
            <ArticleId IdType="pubmed">32079427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pustenko A, Nocentini A, Balašova A, et al. . 
Aryl derivatives of 3H-1,2-benzoxathiepine 2,2-dioxide as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem
2020;35:245–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6896485</ArticleId>
            <ArticleId IdType="pubmed">31790605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Azab AS, Abdel-Aziz AAM, Bua S, et al. . 
S-substituted 2-mercaptoquinazolin-4(3H)-one and 4-ethylbenzensulfonamides act as potent and selective human carbonic anhydrase IX and XII inhibitors. J Enzyme Inhib Med Chem
2020;35:733–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7144323</ArticleId>
            <ArticleId IdType="pubmed">32189526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli A, Tanini D, Nocentini A, et al. . 
Selenols: a new class of carbonic anhydrase inhibitors. Chem Commun. 2019;55:648–51.</Citation>
        </Reference>
        <Reference>
          <Citation>Krasavin M, Žalubovskis R, Grandāne A, Domračeva I, Zhmurov P, Supuran CT.. 
Sulfocoumarins as dual inhibitors of human carbonic anhydrase isoforms IX/XII and of human thioredoxin reductase. J Enzyme Inhib Med Chem
2020;35:506–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7006680</ArticleId>
            <ArticleId IdType="pubmed">31928252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buran K, Bua S, Poli G, Önen Bayram FE, Tuccinardi T, Supuran CT.. 
Novel 8-substituted coumarins that selectively inhibit human carbonic anhydrase IX and XII. Int J Mol Sci
2019;20:E1208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6429297</ArticleId>
            <ArticleId IdType="pubmed">30857344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chandra KM, Goud NS, Arifuddin M, et al. . 
Synthesis and biological evaluation of novel 4,7-disubstituted coumarins as selective tumor-associated carbonic anhydrase IX and XII inhibitors. Bioorg Med Chem Lett
2021;39:127877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33640442</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meleddu R, Deplano S, Maccioni E, et al. . 
Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives. J Enzyme Inhib Med Chem
2021;36:685–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7899656</ArticleId>
            <ArticleId IdType="pubmed">33602041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thacker PS, Srikanth D, Angeli A, et al. . 
Coumarin-thiourea hybrids show potent carbonic anhydrase IX and XIII inhibitory action. ChemMedChem
2021;16:1252–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33346945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Alterio V, Di Fiore A, et al. . 
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one. Med Res Rev
2018;38:1799–836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29635752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli A, Peat TS, Selleri S, Saleh Alfawaz Altamimi A, Supuran CT, Carta F.. 
X-ray crystallography of epacadostat in adduct with carbonic anhydrase IX. Bioorg Chem
2020;97:103669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32088421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akocak S, Güzel-Akdemir Ö, Kishore Kumar Sanku R, et al. . 
Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorg Chem
2020;103:104204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7846937</ArticleId>
            <ArticleId IdType="pubmed">32891000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nocentini A, Bua S, Lomelino CL, et al. . 
Discovery of new sulfonamide carbonic anhydrase IX inhibitors incorporating nitrogenous bases. ACS Med Chem Lett
2017;8:1314–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5733260</ArticleId>
            <ArticleId IdType="pubmed">29259754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Shi K, Sabet ZF, et al. . 
New power of self-assembling carbonic anhydrase inhibitor: short peptide-constructed nanofibers inspire hypoxic cancer therapy. Sci Adv
2019;5:eaax0937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6731069</ArticleId>
            <ArticleId IdType="pubmed">31523712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nocentini A, Angeli A, Carta F, et al. . 
Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase. J Enzyme Inhib Med Chem
2021;36:561–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7901698</ArticleId>
            <ArticleId IdType="pubmed">33615947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra CB, Tiwari M, Supuran CT.. 
Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today?
Med Res Rev
2020;40:2485–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32691504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov
2020;15:671–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32208982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT.. 
The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett
2009;19:4102–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19527930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT.. 
Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett
2007;17:4866–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17588751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber A, Casini A, Heine A, et al. . 
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem
2004;47:550–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14736236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahboubi-Rabbani M, Zarghi A.. 
Dual human carbonic anhydrase/cyclooxygenase-2 inhibitors: a promising approach for cancer treatment. Anticancer Agents Med Chem
2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Cho EJ, Yu SJ, Kim K, et al. . 
Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. J Bioenerg Biomembr
2019;51:121–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30746618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabana AM, Mondal UK, Alam MR, et al. . 
pH-sensitive multiligand gold nanoplatform targeting carbonic anhydrase IX enhances the delivery of doxorubicin to Hypoxic tumor spheroids and overcomes the hypoxia-induced chemoresistance. ACS Appl Mater Interfaces
2018;10:17792–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6338346</ArticleId>
            <ArticleId IdType="pubmed">29733576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd NH, Walker K, Fried J, et al. . 
Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight
2017;2:92928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752277</ArticleId>
            <ArticleId IdType="pubmed">29263302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Logsdon DP, Grimard M, Luo M, et al. . 
Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther
2016;15:2722–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5097013</ArticleId>
            <ArticleId IdType="pubmed">27535970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chafe SC, McDonald PC, Saberi S, et al. . 
Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically. Cancer Immunol Res
2019;7:1064–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31088846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruzzolini J, Laurenzana A, Andreucci E, et al. . 
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. J Enzyme Inhib Med Chem
2020;35:391–7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6968260</ArticleId>
            <ArticleId IdType="pubmed">31865754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol
2020;12:603–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7751321</ArticleId>
            <ArticleId IdType="pubmed">33364855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zatovicova M, Jelenska L, Hulikova A, et al. . 
Monoclonal antibody G250 targeting CA IX: binding specificity, internalization and therapeutic effects in a non-renal cancer model. Int J Oncol
2014;45:2455–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25230982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siebels M, Rohrmann K, Oberneder R, et al. . 
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol
2011;29:121–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20512580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bleumer I, Knuth A, Oosterwijk E, et al. . 
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer
2004;90:985–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2410216</ArticleId>
            <ArticleId IdType="pubmed">14997194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Testa C, Papini AM, Zeidler R, et al. . 
First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors. J Enzyme Inhib Med Chem
2022;37:592–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8786240</ArticleId>
            <ArticleId IdType="pubmed">35057692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antal I, Koneracka M, Kubovcikova M, et al. . 
Targeting of carbonic anhydrase IX-positive cancer cells by glycine-coated superparamagnetic nanoparticles. Colloids Surf B Biointerfaces
2021;205:111893.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34116397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cazzamalli S, Dal Corso A, Widmayer F, Neri D.. 
Chemically defined antibody- and small molecule-drug conjugates for in vivo tumor targeting applications: a comparative analysis. J Am Chem Soc. 2018;140:1617–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5844464</ArticleId>
            <ArticleId IdType="pubmed">29342352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tatiparti K, Rauf MA, Sau S, Iyer AK.. 
Carbonic anhydrase-IX guided albumin nanoparticles for hypoxia-mediated triple-negative breast cancer cell killing and imaging of patient-derived tumor. Molecules
2020;25:2362.</Citation>
        </Reference>
        <Reference>
          <Citation>Santos E da S, Nogueira KAB, Fernandes LCC, et al. . 
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int J Pharm
2021;592:120082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33188892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krall N, Pretto F, Decurtins W, Bernardes GJL, Supuran CT, Neri D.. 
A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl
2014;53:4231–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24623670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrul HM, Schatz CA, Kopitz CC, et al. . 
Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther
2012;11:340–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22147747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zatovicova M, Jelenska L, Hulikova A, et al. . 
Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr Pharm Des
2010;16:3255–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20819068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thacker PS, Alvala M, Arifuddin M, Angeli A, Supuran CT.. 
Design, synthesis and biological evaluation of coumarin-3-carboxamides as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem
2019;86:386–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30763885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thacker PS, Angeli A, Argulwar OS, Tiwari PL, Arifuddin M, Supuran CT.. 
Design, synthesis and biological evaluation of coumarin linked 1,2,4-oxadiazoles as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem
2020;98:103739.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32193032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thacker PS, Sridhar Goud N, Argulwar OS, et al. . 
Synthesis and biological evaluation of some coumarin hybrids as selective carbonic anhydrase IX and XII inhibitors. Bioorg Chem
2020;104:104272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32961467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelrahman MA, Eldehna WM, Nocentini A, et al. . 
Novel benzofuran-based sulphonamides as selective carbonic anhydrases IX and XII inhibitors: synthesis and in vitro biological evaluation. J Enzyme Inhib Med Chem
2020;35:298–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6913630</ArticleId>
            <ArticleId IdType="pubmed">31809607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelrahman MA, Ibrahim HS, Nocentini A, et al. . 
Novel 3-substituted coumarins as selective human carbonic anhydrase IX and XII inhibitors: synthesis, biological and molecular dynamics analysis. Eur J Med Chem
2021;209:112897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33038795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mboge MY, Chen Z, Wolff A, et al. . 
Selective inhibition of carbonic anhydrase IX over carbonic anhydrase XII in breast cancer cells using benzene sulfonamides: disconnect between activity and growth inhibition. PLOS One
2018;13:e0207417.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6242694</ArticleId>
            <ArticleId IdType="pubmed">30452451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Battke C, Kremmer E, Mysliwietz J, et al. . 
Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic anhydrase XII. Cancer Immunol Immunother
2011;60:649–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21298264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gondi G, Mysliwietz J, Hulikova A, et al. . 
Antitumor efficacy of a monoclonal antibody that inhibits the activity of cancer-associated carbonic anhydrase XII. Cancer Res
2013;73:6494–503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24030978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Neubeck B, Gondi G, Riganti C, et al. . 
An inhibitory antibody targeting carbonic anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo. Int J Cancer
2018;143:2065–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29786141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uda NR, Stenner F, Seibert V, et al. . 
Humanized monoclonal antibody blocking carbonic anhydrase 12 enzymatic activity leads to reduced tumor growth in vitro. Anticancer Res
2019;39:4117–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31366496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dekaminaviciute D, Kairys V, Zilnyte M, et al. . 
Monoclonal antibodies raised against 167-180 aa sequence of human carbonic anhydrase XII inhibit its enzymatic activity. J Enzyme Inhib Med Chem
2014;29:804–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24400872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moeker J, Peat TS, Bornaghi LF, Vullo D, Supuran CT, Poulsen SA.. 
Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. J Med Chem
2014;57:3522–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24689792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eldehna WM, Taghour MS, Al-Warhi T, et al. . 
Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem
2022;37:531–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8745369</ArticleId>
            <ArticleId IdType="pubmed">34991416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mokhtari RB, Homayouni TS, Baluch N, et al. . 
Combination therapy in combating cancer. Oncotarget
2017;8:38022–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5514969</ArticleId>
            <ArticleId IdType="pubmed">28410237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Havránková E, Garaj V, Mascaretti Š, et al. . 
Novel 1,3,5-triazinyl aminobenzenesulfonamides incorporating aminoalcohol, aminochalcone and aminostilbene structural motifs as potent anti-VRE agents, and carbonic anhydrases I, II, VII, IX, and XII inhibitors. Int J Mol Sci
2021;23:231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8745223</ArticleId>
            <ArticleId IdType="pubmed">35008657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giovannuzzi S, D’Ambrosio M, Luceri C, et al. . 
Aromatic sulfonamides including a sulfonic acid tail: new membrane impermeant carbonic anhydrase inhibitors for targeting selectively the cancer-associated isoforms. Int J Mol Sci
2021;23:461.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8745330</ArticleId>
            <ArticleId IdType="pubmed">35008884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Mohsen HT, El Kerdawy AM, Omar MA, et al. . 
Application of the dual-tail approach for the design and synthesis of novel thiopyrimidine-benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors. Eur J Med Chem
2022;228:114004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34847409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eldeeb AH, Abo-Ashour MF, Angeli A, et al. . 
Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies. Eur J Med Chem
2021;221:113486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33965860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Zhang G, Wang X, Li XF.. 
Is carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?
Future Oncol
2015;11:1531–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4976829</ArticleId>
            <ArticleId IdType="pubmed">25963430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams A, van Brussel ASA, Vermeulen JF, et al. . 
The potential of hypoxia markers as target for breast molecular imaging–a systematic review and meta-analysis of human marker expression. BMC Cancer
2013;13:538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3903452</ArticleId>
            <ArticleId IdType="pubmed">24206539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer A, Höckel M, Vaupel P.. 
Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix. Clin Cancer Res
2005;11:7220–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16243791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Said HM, Supuran CT, Hageman C, et al. . 
Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des
2010;16:3288–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20819065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamie K, Donin NM, Klöpfer P, et al. . 
Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3:913–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5824229</ArticleId>
            <ArticleId IdType="pubmed">27787547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Federici C, Lugini L, Marino ML, et al. . 
Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem
2016;31:119–125.</Citation>
        </Reference>
        <Reference>
          <Citation>Chiche J, Ilc K, Laferrière J, et al. . 
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res
2009;69:358–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19118021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meijer TWH, Bussink J, Zatovicova M, et al. . 
Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model. PLOS One. 2014;9:e108068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4167542</ArticleId>
            <ArticleId IdType="pubmed">25225880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer AC, Sorger PK.. 
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell
2017;171:1678–1691.e13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5741091</ArticleId>
            <ArticleId IdType="pubmed">29245013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalinin S, Malkova A, Sharonova T, et al. . 
Carbonic anhydrase IX inhibitors as candidates for combination therapy of solid tumors. Int J Mol Sci
2021;22:13405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8705727</ArticleId>
            <ArticleId IdType="pubmed">34948200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Darvin P, Toor SM, Sasidharan Nair V, Elkord E.. 
Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med
2018;50:1–11.</Citation>
        </Reference>
        <Reference>
          <Citation>Topatana W, Juengpanich S, Li S, et al. . 
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol
2020;13:118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7470446</ArticleId>
            <ArticleId IdType="pubmed">32883316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDonald PC, Chafe SC, Brown WS, et al. . 
Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia. Gastroenterology
2019;157:823–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31078621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song X, Zhu S, Xie Y, et al. . 
JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice. Gastroenterology
2018;154:1480–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880694</ArticleId>
            <ArticleId IdType="pubmed">29248440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang Y, Verbiest T, Devery AM, et al. . 
Hypoxia potentiates the radiation-sensitizing effect of olaparib in human non-small cell lung cancer xenografts by contextual synthetic lethality. Int J Radiat Oncol Biol Phys
2016;95:772–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4856738</ArticleId>
            <ArticleId IdType="pubmed">27020103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teixeira SA, Viapiano MS, Andrade AF, et al. . 
The carbonic anhydrase inhibitor E7070 sensitizes glioblastoma cells to radio- and chemotherapy and reduces tumor growth. Mol Neurobiol
2021;58:4520–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34085182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chafe SC, Vizeacoumar FS, Venkateswaran G, et al. . 
Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors. Sci Adv
2021;7:eabj0364.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8397268</ArticleId>
            <ArticleId IdType="pubmed">34452919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT.
Multitargeting approaches involving carbonic anhydrase inhibitors: hybrid drugs against a variety of disorders. J Enzyme Inhib Med Chem. 2021;36:1702–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8330743</ArticleId>
            <ArticleId IdType="pubmed">34325588</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
